Zimmer Biomet has reported Q2 revenues of around $2.18bn, denoting a year-over-year (YoY) uptick of 4.8%, and a revised full year outlook.
Zimmer’s knees segment was its strongest performer in Q2, with sales totalling $828.9m, followed by S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) at $586m, and hips at $562.7m. However, while Zimmer’s technology and data, bone cement and surgical segment drew in the lowest profits in Q2 at $199.4m, this segment saw the largest YoY growth at 21.1%, followed by S.E.T. at 6.4% and hips at 5%. Meanwhile, YoY growth in knees remained flat at 0.4%.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The orthopaedics giant now expects 2026 revenue growth to land in the 3.9% to 4.9% range, up from 2.5% to 4.5% previously, with earnings now mooted to come in at $8.47-$8.59 per diluted share, up from $8.40-$8.55 previously.
Zimmer released its Q2 financials ahead of market open. The company’s shares on the New York Stock Exchange (NYSE) rose by over 5% to around $101.00 at market open on 5 August, up from $95.81 previously. Zimmer Biomet has a market cap of $19.63bn.
Reflecting on Zimmer’s Q2 performance, Tornos, said: “With a strong first half, healthy underlying markets, go-to-market changes progressing as planned and continued momentum from our innovation cycle, we are raising our revenue and adjusted earnings per share (EPS) guidance for the year.
“Importantly, we continue to advance our strategic priorities and remain confident our efforts will strengthen our business, build the boldest leader in medtech, and better position Zimmer Biomet to deliver consistent, durable growth over the long term.”
Zimmer’s revisions to its 2026 outlook come amid a series of structural evolutions the company is undergoing. Upon releasing its 2025 results, Zimmer CEO Ivan Tornos highlighted that the company previously tempered its 2026 outlook given its planned investment into a stronger, specialised sales force in the US, as outlined at the J.P. Morgan HealthCare conference in January.
At the time, Tornos also shared that the degree of success of both international market growth and new product adoption cycles were additional factors in the company’s 2026 forecast.
